Jorna welcomes Dr. Yong Dai to join as its President

I am thrilled to announce that Yong Dai has joined Jorna Therapeutics as our new President!

Yong brings an unparalleled track record of leadership and innovation in biologics and gene therapy drug development. His contributions to the field are nothing short of extraordinary:

🔹 Former founder and CEO of Frontera Therapeutics (over $160M raised and four pipelines advanced to clinical stage)

🔹 Former CTO at Prevail Therapeutics, where he spearheaded the CMC organization and advanced multiple AAV gene therapies to clinical trials. He was a key player in Prevail’s IPO on NASDAQ and its subsequent acquisition by Eli Lilly for over $1B.

🔹 At uniQure, he led the CMC development for pioneering gene therapy programs, including Hemgenix® and Glybera®—the world’s first commercially approved AAV gene therapies.

🔹 Leadership roles at Shire Pharmaceuticals and ImmunoGen, where he oversaw the development of blockbuster therapies like Kadcyla® (T-DM1), the first ADC to achieve annual sales exceeding $1B.

We couldn’t be more excited about the wealth of expertise and visionary leadership Yong brings to Jorna. As we continue our mission to redefine the future of RNA editing, his insights will be invaluable in driving us forward.

Please join me in welcoming Yong Dai to the Jorna team! 🎉